Eiger BioPharmaceuticals (EIGR) Reports In-Line Q4 EPS

Eiger BioPharmaceuticals (NASDAQ: EIGR) reported Q4 EPS of ($0.64), in-line with the analyst estimate of ($0.64). Revenue for the quarter came in at $3.36 million versus the consensus estimate of $3.34 million.

For earnings history and earnings-related data on Eiger BioPharmaceuticals (EIGR) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• The LGL Group (LGL) Misses Q2 EPS by 8c
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance